---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-292080"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2023-12-11T23:59:59+00:00"
generated_at: "2026-06-07T14:59:32.963987+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TScan Phase 1 TCR-T data: 6/6 patients achieve complete donor chimerism and MRD negativity; 0/4 controls

## Summary
- All 6 evaluable patients treated with TSC-100 or TSC-101 achieved complete donor chimerism and MRD negativity; none of 4 control-arm patients achieved these endpoints.
- One AML patient MRD-positive post-HCT converted to MRD-negative after TSC-101 treatment.
- Control arm: one TP53-mutated MDS patient relapsed at ~6 months; two others had worsening chimerism requiring clinical intervention.
- Dose escalation reached third and final level with no dose-limiting toxicities; recommended Phase 2 dose expected from this level.
- Company hosting virtual KOL event Dec 11 to discuss data; 10 clinical sites active with expansion cohorts planned.

## SEC filing metadata
- accession: 0001193125-23-292080
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2023-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000119312523292080/0001193125-23-292080-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000119312523292080/d840458d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-292080
- JSON: https://secwatch.observer/filing/0001193125-23-292080.json
- Plain text: https://secwatch.observer/filing/0001193125-23-292080.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.